Skip to main content

Table 1 Characteristics of included studies

From: Prevalence of metabolic syndrome among HIV-positive and HIV-negative populations in sub-Saharan Africa—a systematic review and meta-analysis

  Author and publication year Study design, settings, and year Sex Mean age (years) Matched mean age (years) HIV status Hypertension definition criteria used for MetS estimate MetS definition criteria
HIV+ HIV− HIV+ HIV−
1 Amusa et al., 2016 [33] Cross sectional, Nigeria, NS Both 41 ± 7/40 ± 8 α 41  ±  7 40  ±  8 150 50 Not stated Other
2 Ayodele et al., 2012 [32] Cross sectional, Nigeria, NS Both 39.5–9.3 NA NA 291 NA ≥ 130/85 and on antihypertensive treatment IDF, ATP, JIS
3 Berhane et al., 2012 [34] Cross-sectional, Ethiopia, 2010 Both 18 and above NA NA 313 NA ≥140/90 and on antihypertensive treatment ATP
4 Tesfaye et al., 2014 [42] Cross sectional, Ethiopia, 2012–13 Both 32.7 ± 9.7 (ART) 32.6 ± 7.8 (naïve) NA NA 374 NA ≥ 130/85 and on antihypertensive treatment IDF, ATP
5 Sobieszczyk et al., 2016 [29] Cross-sectional, South Africa, 2013 Female Median 24 years NA NA 160 NA ≥ 130/85 and on antihypertensive treatment ATP
6 Obirikorang et al., 2016 [41] Cross sectional, Ghana,2013 Both 40.3 ± 0.8 NA NA 433 NA ≥ 130/85 and on antihypertensive treatment IDF, ATP, WHO
7 Ngatchou et al., 2013 [40] Cross sectional, Cameroon, 2009–10 Both 41 ± 12α/39 ± 10 39.0 ± 10.0 41 ± 12 108 96 ≥ 140/90 and on antihypertensive treatment IDF
8 Fourie et al., 2010 [35] Case control, South Africa, 2005 Both 44 ± 7.81α/44 ± 8.04 44.0 ± 8.04 44.0 ± 7.81 300 300 ≥ 130/85 and on antihypertensive treatment IDF, ATP
9 Muhammad et al., 2013 [45] Cross sectional, Nigeria, 2009 Both 32.5 ± 7.55 NA NA 200 NA ≥ 140/90 and on antihypertensive treatment IDF
10 Mbunkah et al., 2014 [38] Cross sectional, Cameroon, 2010–11 Both 18–70 41.1 ± 11.2 47.3 ± 13.7 173 50 ≥ 130/85 and on antihypertensive treatment ATP
11 Guehi et al., 2016 [30] Randomized control trial, Ivory Coast, 2008–14 Both 29–42 NA NA 755 NA ≥ 140/90 and on antihypertensive treatment ATP
12 Mashinya et al., 2015 [37] Cross sectional, South Africa, 2013–14 Both 44.8 ± 11.8 NA NA 214 NA ≥ 140/90 and on antihypertensive treatment ATP
13 Guira et al., 2016 [31] Cross sectional, Burkina Faso, 2011 Both 44.8 + 7.4 NA NA 300 NA ≥ 130/85 and on antihypertensive treatment IDF
14 Hirigo et al., 2016 [36] Cross sectional, Ethiopia, 2013 Both 26.5–38 NA NA 185 NA ≥ 130/85 and on antihypertensive treatment IDF, ATP
15 Zannou et al., 2009 [28] Cohort, Benin, 2004–09 Both 38.0 ± 9.7 NA NA 79 NA ≥ 130/85 and on antihypertensive treatment IDF
16 Muyanja et al., 2016 [39] Cross sectional, Uganda, NS Both 30–43 NA NA 250 NA ≥ 140/90 and on antihypertensive treatment ATP
17 Adébayo et al., 2015 [44] Cross-sectional, Benin, NS Both 40,7 ± 9,71 NA NA 244 NA ≥130/85 and on antihypertensive treatment Other
18 Sawadogo et al., 2005 [43] Cross sectional, Burkina Faso, 2011 Both 41.4 ± 8.8 NA NA 400 NA ≥ 140/90 and on antihypertensive treatment IDF, ATP
  1. NA not applicable, IDF International Diabetes Federation, ATP Adult Treatment Panel III report of the National Cholesterol Education Program, WHO World Health Organization, α HIV negative